WS Investor
12 Nov 2026, 16:09
Pfizer Secures Up to $1.5 Billion From Blackstone to Fund Monthly GLP-1 Obesity Program
Pfizer (NYSE: PFE) and Blackstone Life Sciences announced a strategic co-funding agreement under which Blackstone-managed funds will provide up to $1.5 billion through 2028 to support development of berobenatide, Pfizer’s investigational monthly GLP-1 receptor agonist for chronic weight management and obesity-related conditions.
Under the agreement, Blackstone will fund a portion of berobenatide’s development costs in exchange for potential milestone-based payments tied to U.S. regulatory approval of monthly injectable berobenatide monotherapy and achievement of certain commercial sales milestones.
Pfizer retains full ownership, operational control and decision-making authority over the program. Blackstone will not receive rights to the drug itself, limiting the arrangement primarily to development financing and milestone economics.
Berobenatide, also known as PF’3944, is being positioned as a potential first-in-class monthly GLP-1 receptor agonist. Pfizer plans more than 20 obesity and related-comorbidity trials in 2026, including 10 ongoing or planned Phase 3 studies evaluating berobenatide in chronic weight management as well as conditions such as knee osteoarthritis and obstructive sleep apnea.
The company is also studying berobenatide in combination with other nutrient-stimulated hormone peptides, including amylin analogs, as it builds a broader cardiometabolic pipeline.
The financing agreement allows Pfizer to advance an expensive late-stage obesity development program while preserving capital for other pipeline priorities. For Blackstone, the transaction provides exposure to a potentially large commercial opportunity without acquiring ownership of the underlying drug asset.
The deal also highlights the growing role of external capital in funding large pharmaceutical development programs, particularly in obesity, where clinical programs are becoming increasingly broad and costly as companies compete for share in the rapidly expanding GLP-1 market.
Pfizer (NYSE: PFE) and Blackstone Life Sciences announced a strategic co-funding agreement under which Blackstone-managed funds will provide up to $1.5 billion through 2028 to support development of berobenatide, Pfizer’s investigational monthly GLP-1 receptor agonist for chronic weight management and obesity-related conditions.
Under the agreement, Blackstone will fund a portion of berobenatide’s development costs in exchange for potential milestone-based payments tied to U.S. regulatory approval of monthly injectable berobenatide monotherapy and achievement of certain commercial sales milestones.
Pfizer retains full ownership, operational control and decision-making authority over the program. Blackstone will not receive rights to the drug itself, limiting the arrangement primarily to development financing and milestone economics.
Berobenatide, also known as PF’3944, is being positioned as a potential first-in-class monthly GLP-1 receptor agonist. Pfizer plans more than 20 obesity and related-comorbidity trials in 2026, including 10 ongoing or planned Phase 3 studies evaluating berobenatide in chronic weight management as well as conditions such as knee osteoarthritis and obstructive sleep apnea.
The company is also studying berobenatide in combination with other nutrient-stimulated hormone peptides, including amylin analogs, as it builds a broader cardiometabolic pipeline.
The financing agreement allows Pfizer to advance an expensive late-stage obesity development program while preserving capital for other pipeline priorities. For Blackstone, the transaction provides exposure to a potentially large commercial opportunity without acquiring ownership of the underlying drug asset.
The deal also highlights the growing role of external capital in funding large pharmaceutical development programs, particularly in obesity, where clinical programs are becoming increasingly broad and costly as companies compete for share in the rapidly expanding GLP-1 market.
